Market Cap
$2.5B
BEAM
Beam Therapeutics Inc.
$24.33 ▼ -0.27%
Prev close $24.39Market cap$2.5B
ConsensusStrong Buy
12-mo target$52.15 (+114.4%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)31 New Institutional Positions11 Institutional Exits Biotech & Drug DiscoveryGenomics & Gene Editing
Snapshot
The big-picture read on BEAM right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (87%)
Inst. Holders
50 funds
Inst. Value
$2.9B
Inst. Activity
31 buys / 11 sells
Insider Activity
$0.00 buy / $17.3M sell
Insider Net $
-$17.3M
Social Sentiment
50° Neutral
SEC Reports
5
Press Releases
2
Price chart 30d -17.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Sep 24, 2026 Insider
Aug 15, 2026 SEC Ciaramella Giuseppe gifted 123,407 shares
President
Eight institutional investors accumulated $59.7M in BEAM during Q2 2026, led by Morgan Stanley doubling its stake to $67
INST-CLUSTER — Impact 5/10
Jul 27, 2026 Insider
Jul 2, 2026 SEC Simon Amy sold 16,667 shares
Chief Medical Officer @ $25.74 ($429.0K)
A cluster of insider selling at Beam Therapeutics materialized over June 26-30, 2026, totaling $8.95M. The CEO exercised
CLUSTER — Impact 5/10
CEO John M. Evans exercised options and sold shares worth ~$1.26M, while 10% owner FMR LLC sold 251,488 shares (~$8.87M)
CLUSTER — Impact 4/10
Jun 30, 2026 Insider
Evans John M. sold 23,100 shares
CEO @ $34.26 ($791.5K)
Jun 30, 2026 Inst.
MORGAN STANLEY — DOUBLED
1,950,969 shares ($67.0M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
87% rate it Buy or better · 23 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 9, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Aug 25, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jul 8, 2026 | B of A Securities | REITERATE | Buy | 54% |
| Jul 7, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 13, 2026 | Bernstein | MAINTAIN | Outperform | 51% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 9 | 11 | 3 | 0 | 0 | 87% | |
| Aug 1, 2026 | 9 | 11 | 3 | 0 | 0 | 87% | |
| Jul 1, 2026 | 11 | 11 | 3 | 0 | 0 | 88% | |
| Jun 1, 2026 | 11 | 11 | 3 | 0 | 0 | 88% | |
| May 1, 2026 | 11 | 11 | 3 | 0 | 0 | 88% | |
| Apr 1, 2026 | 11 | 11 | 3 | 0 | 0 | 88% | |
| Mar 1, 2026 | 11 | 11 | 3 | 0 | 0 | 88% | |
| Feb 1, 2026 | 11 | 10 | 3 | 0 | 0 | 88% |
Price targets
Where 13 covering analysts think BEAM trades over the next 12 months.
$52.15 +114.4% upside Strong Buy
Current$24.33 Low$26.00 Median$45.00 High$80.00 13 analysts
$26.00$80.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 1 bullish, 1 bearish, 1 mixed, 2 neutral · avg impact 4.2/10.Plus 2 press releases.
BULLISHINST-CLUSTER5/10
Eight institutional investors accumulated $59.7M in BEAM during Q2 2026, led by Morgan Stanley doubl
Aug 15, 2026
MIXEDCLUSTER5/10
A cluster of insider selling at Beam Therapeutics materialized over June 26-30, 2026, totaling $8.95
Jul 2, 2026
BEARISHCLUSTER4/10
CEO John M. Evans exercised options and sold shares worth ~$1.26M, while 10% owner FMR LLC sold 251,
Jul 2, 2026
NEUTRALDEFA14A3/10
Beam Therapeutics Inc. (BEAM) has filed its definitive proxy statement (DEFA14A) for the 2026 annual
Apr 17, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company"
Oct 1, 2026
short_volume
Short Volume: BEAM — 66.2% short (0.4M / 0.6M)
Short: 429,226 | Exempt: 17,230 | TRF Vol: 648,162 | Short Ratio: 66.2% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
short_volume
Short Volume: BEAM — 70.7% short (0.4M / 0.6M)
Short: 397,105 | Exempt: 1 | TRF Vol: 561,450 | Short Ratio: 70.7% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: BEAM — 69.4% short (0.4M / 0.5M)
Short: 379,881 | Exempt: 1,000 | TRF Vol: 547,575 | Short Ratio: 69.4% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: BEAM — 59.0% short (0.3M / 0.5M)
Short: 297,118 | Exempt: 1,001 | TRF Vol: 503,379 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.17 | $-1.28–$-1.05 | -6.3% | +0.0% | 4↑ 5↓ | $0.0B | 13 |
| Next Q | $-1.19 | $-1.34–$-1.06 | -150.9% | +0.0% | 3↑ 6↓ | $0.0B | 13 |
| Current FY | $-4.45 | $-4.76–$-4.24 | -449.8% | +0.0% | 4↑ 5↓ | $0.0B | 14 |
| Next FY | $-4.74 | $-5.72–$-3.56 | -6.5% | +0.0% | 5↑ 3↓ | $0.1B | 12 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.170 | — |
| 7d ago | $-1.170 | — |
| 30d ago | $-1.170 | — |
| 60d ago | $-1.174 | +0.005 |
| 90d ago | $-1.181 | +0.011 |
Institutional ownership
Which big funds own BEAM (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $2.9B total value (84,192,474 shares) as of 2026-Q2. Top holders: FMR, FARALLON, ARK. Net buying activity: 31 institutions added/increased vs 11 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 12,609,002 | $432.7M | 15.0% | — |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 10,236,396 | $351.3M | 12.2% | — |
| ARK Investment Management LLC | 10,234,862 | $351.3M | 12.2% | — |
| BlackRock, Inc. | 8,997,542 | $308.8M | 10.7% | — |
| STATE STREET CORP | 5,827,122 | $200.0M | 6.9% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,921,259 | $168.9M | 5.8% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,599,437 | $157.9M | 5.5% | — |
| Sumitomo Mitsui Trust Group, Inc. | 3,455,043 | $118.6M | 4.1% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,596,963 | $89.1M | 3.1% | — |
| DIMENSIONAL FUND ADVISORS LP | 2,225,844 | $76.4M | 2.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 648,264 | 1,950,969 | +201.0% | $67.0M |
| GOLDMAN SACHS GROUP INC | ADD | 1,005,743 | 1,310,059 | +30.3% | $45.0M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | 700,647 | 1,067,883 | +52.4% | $36.6M |
| BANK OF AMERICA CORP /DE/ | ADD | 538,290 | 720,648 | +33.9% | $24.7M |
| UBS Group AG | TRIM | 826,061 | 574,814 | -30.4% | $19.7M |
| MARSHALL WACE, LLP | DOUBLED | 139,241 | 478,980 | +244.0% | $16.4M |
| JUPITER ASSET MANAGEMENT LTD | DOUBLED | 24,060 | 445,718 | +1752.5% | $15.3M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | NEW | — | 296,294 | — | $10.2M |
| Qube Research & Technologies Ltd | NEAR_EXIT | 1,084,768 | 194,083 | -82.1% | $6.7M |
| WELLS FARGO & COMPANY/MN | ADD | 132,249 | 189,389 | +43.2% | $6.5M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 48 transactions. Net -$17.3M — $0.00 bought, $17.3M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 24, 2026 | Ciaramella Giuseppe | President | GIFT | 123,407 | — | — |
| Jul 27, 2026 | Simon Amy | Chief Medical Officer | SELL | 16,667 | $25.74 | $429.0K |
| Jun 30, 2026 | Evans John M. | CEO | SELL | 23,100 | $34.26 | $791.5K |
| Jun 30, 2026 | Evans John M. | CEO | EXERCISE | 25,000 | $1.03 | $25.8K |
| Jun 30, 2026 | Evans John M. | CEO | SELL | 1,900 | $34.84 | $66.2K |
| Jun 30, 2026 | Simon Amy | Chief Medical Officer | SELL | 373 | $34.73 | $13.0K |
| Jun 29, 2026 | Evans John M. | CEO | EXERCISE | 18,663 | $0.6700 | $12.5K |
| Jun 29, 2026 | Evans John M. | CEO | SELL | 13,421 | $35.13 | $471.5K |
| Jun 29, 2026 | Evans John M. | CEO | EXERCISE | 6,337 | $1.03 | $6.5K |
| Jun 29, 2026 | Evans John M. | CEO | SELL | 11,579 | $35.91 | $415.8K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for BEAM.
Shares short
25,884,796
Settlement Sep 15, 2026
Change vs prior
+0.3%
Semi-monthly cycle
Days to cover
12.6
At avg daily volume
Of shares outstanding
≈25.1%
Estimate — not % of float
All BEAM filing & press-release reports (7)
- INST-CLUSTER reportAug 15, 2026
- CLUSTER reportJul 2, 2026
- CLUSTER reportJul 2, 2026
- PRESS-RELEASE reportMay 12, 2026
- DEFA14A reportApr 17, 2026
- PRESS-RELEASE reportMar 25, 2026
- 8-K reportMar 5, 2026